Evidence map›Paper›PMID 41256484›Full record

ArticlebioRxiv : the preprint server for biology2025

Methionine regulates antitumor function of CD8

Tian Zhao, Gillian A Carleton, Sarah Macpherson, Madison Shiyuk, Joseph Monaghan, Jun Han, Oro Uchenunu, Robert Rottapel, Ralph J DeBerardinis, Kelly M Stewart and 6 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Tian ZhaoDepartment of Biochemistry and Microbiology, University of Victoria, Victoria, BC, Canada.
Gillian A CarletonDepartment of Biochemistry and Microbiology, University of Victoria, Victoria, BC, Canada.
Sarah MacphersonDepartment of Basic and Translational Research, BC Cancer Research Institute, BC Cancer, Victoria, BC, Canada.
Madison ShiyukDepartment of Biochemistry and Microbiology, University of Victoria, Victoria, BC, Canada.
Joseph MonaghanCentre for Health and Environmental Mass Spectrometry, Vancouver Island University, Nanaimo, BC, Canada.
Jun HanUniversity of Victoria Genome BC Proteomics Centre, University of Victoria, Victoria, BC, Canada.
Oro UchenunuPrincess Margaret Cancer Center, University Health Network, University of Toronto, Toronto, ON, Canada.
Robert RottapelPrincess Margaret Cancer Center, University Health Network, University of Toronto, Toronto, ON, Canada.
Ralph J DeBerardinisChildren's Medical Center Research Institute, University of Texas Southwestern, Dallas, TX, United States.
Kelly M StewartAgios Pharmaceuticals, Cambridge, MA, United States.
Bo-Hyun KimDepartment of Biochemistry and Microbiology, University of Victoria, Victoria, BC, Canada.
Juan AusióDepartment of Biochemistry and Microbiology, University of Victoria, Victoria, BC, Canada.
David R GoodlettDepartment of Biochemistry and Microbiology, University of Victoria, Victoria, BC, Canada.ORCID 0000-0002-8045-8200
Helena PětrošováDepartment of Biochemistry and Microbiology, University of Victoria, Victoria, BC, Canada.
Kyle D DuncanCentre for Health and Environmental Mass Spectrometry, Vancouver Island University, Nanaimo, BC, Canada.
Julian J LumDepartment of Biochemistry and Microbiology, University of Victoria, Victoria, BC, Canada.

Funding

Metabolic Regulators of Tumor Growth and ProgressionR35CA220449 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI RALPH J DEBERARDINIS · 2017 to 2026
$9.4M
NCI NIH HHS R35 CA220449
6 · The paper itself

Abstract

Methionine is an essential amino acid critical for T cell activation. While methionine restriction (MR) combined with immune checkpoint blockade has been shown to enhance T cell function, the impact of methionine on adoptive T cell therapies is largely unexplored. Here, we examined the functionality of T cells under MR and pharmaceutical inhibition of the methionine cycle (MAT2Ai), using primary T cells and a murine adoptive T cell therapy model.

Identifiers

PMID41256484
PMCPMC12621867

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.